Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Hasenclever

Showing results (41-50 of 98) with videos related to

Pageof 10
Sort By:
Plos One|October 30, 2020
Factors influencing the bias between blood gas analysis versus central laboratory hemoglobin testing. A secondary analysis of a randomized controlled trialLinda Tanner, Simone Lindau, Markus Velten, et al.
Blood|March 16, 2004
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHLMichael Pfreundschuh, Lorenz Trümper, Marita Kloess, et al.
Springerplus|January 24, 2014
Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHLKarin Hohloch, Carsten Zwick, Marita Ziepert, et al.
Cancer|May 26, 2007
Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphomaChristine Mauz-Körholz, Stephanie Gorde-Grosjean, Dirk Hasenclever, et al.
Leukemia & Lymphoma|September 11, 2014
Feasibility of VECOPA, a dose-intensive chemotherapy regimen for children and adolescents with intermediate and advanced stage Hodgkin lymphoma: results of the GPOH-HD-2002/VECOPA pilot trialChristine Mauz-Körholz, Dirk Hasenclever, Volker Holzendorf, et al.
Leukemia & Lymphoma|May 10, 2002
Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II studyLuisa Mantovani, Dirk Hasenclever, Rainer Krahl, et al.
Blood|February 26, 2004
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHLMichael Pfreundschuh, Lorenz Trümper, Marita Kloess, et al.
International Journal of Cancer|April 13, 2005
SPOC1, a novel PHD-finger protein: association with residual disease and survival in ovarian cancerGerrit Mohrmann, Jan G Hengstler, Thomas G Hofmann, et al.
Haematologica|June 3, 2008
Recurrent loss of the Y chromosome and homozygous deletions within the pseudoautosomal region 1: association with male predominance in mantle cell lymphomaInga Nieländer, José I Martín-Subero, Florian Wagner, et al.
Arthritis Research & Therapy|May 5, 2009
Association of MICA with rheumatoid arthritis independent of known HLA-DRB1 risk alleles in a family-based and a case control studyHolger Kirsten, Elisabeth Petit-Teixeira, Markus Scholz, et al.
Pageof 10

Showing results (41-50 of 98) with videos related to

Sort By:
Pageof 10
Plos One|October 30, 2020
Factors influencing the bias between blood gas analysis versus central laboratory hemoglobin testing. A secondary analysis of a randomized controlled trialLinda Tanner, Simone Lindau, Markus Velten, et al.
Blood|March 16, 2004
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHLMichael Pfreundschuh, Lorenz Trümper, Marita Kloess, et al.
Springerplus|January 24, 2014
Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHLKarin Hohloch, Carsten Zwick, Marita Ziepert, et al.
Cancer|May 26, 2007
Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphomaChristine Mauz-Körholz, Stephanie Gorde-Grosjean, Dirk Hasenclever, et al.
Leukemia & Lymphoma|September 11, 2014
Feasibility of VECOPA, a dose-intensive chemotherapy regimen for children and adolescents with intermediate and advanced stage Hodgkin lymphoma: results of the GPOH-HD-2002/VECOPA pilot trialChristine Mauz-Körholz, Dirk Hasenclever, Volker Holzendorf, et al.
Leukemia & Lymphoma|May 10, 2002
Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II studyLuisa Mantovani, Dirk Hasenclever, Rainer Krahl, et al.
Blood|February 26, 2004
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHLMichael Pfreundschuh, Lorenz Trümper, Marita Kloess, et al.
International Journal of Cancer|April 13, 2005
SPOC1, a novel PHD-finger protein: association with residual disease and survival in ovarian cancerGerrit Mohrmann, Jan G Hengstler, Thomas G Hofmann, et al.
Haematologica|June 3, 2008
Recurrent loss of the Y chromosome and homozygous deletions within the pseudoautosomal region 1: association with male predominance in mantle cell lymphomaInga Nieländer, José I Martín-Subero, Florian Wagner, et al.
Arthritis Research & Therapy|May 5, 2009
Association of MICA with rheumatoid arthritis independent of known HLA-DRB1 risk alleles in a family-based and a case control studyHolger Kirsten, Elisabeth Petit-Teixeira, Markus Scholz, et al.
Pageof 10